Conference
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
Abstract
e16503
Background: Statins have been associated with favorable effects in various solid malignancies. In prostate cancer, statins may synergize with novel anti-androgen agents enzalutamide and abiraterone via pharmacokinetic interactions and by decreasing substrate availability for androgen de-novo biosynthesis. Methods: Medical records of patients with metastatic castration-resistant prostate cancer (mCRPC) between September, …
Authors
Buonerba C; Sonpavde G; Pond GR; Pagliuca M; Rossetti S; Facchini G; Scagliarini S; Daniele B; Federico P; Morelli F
Volume
35
Pagination
pp. e16503-e16503
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2017
DOI
10.1200/jco.2017.35.15_suppl.e16503
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X